MAP2K7 and cancer: This adaptive intrinsic resistance mechanism, which has been widely observed with treatments with KRASG12Ci in various other cancer types [17, 23, 33, 34, 73], is consistent with the resistance pattern observed for MEK inhibition in HNC [74].